PROM1 and esophageal cancer: CD133 has been shown to be associated with worse prognosis in NSCLC 7, ovarian cancer 8, hepatocellular carcinoma 9, breast cancer 10 and colorectal cancer 11, however its role in esophageal cancer still needs to be investigated.